Restricted accessResearch articleFirst published online 2024-01
Analysis of Interleukin-6 Gene Variants ( rs1800795,rs1800796,rs1554606,rs1800797,rs2069840,rs12700386,and rs2069861 ) as Prognostic Markers in Breast Cancer: A Systematic Review,Meta-Analysis,and Network Analysis
Interleukin-6 (IL-6) has obviously tumor-promoting and tumor-inhibitory effects and can induce an epithelial–mesenchymal transition phenotype in human breast cancer (BC) cells and implicate its potential to promote BC metastasis. Herein, we aimed to evaluate the association of IL-6 variants (rs1800795, rs1800796, rs1554606, rs1800797, rs2069840, rs12700386, and rs2069861) with the susceptibility to BC. The databases of PubMed/Medline, Web of Science, Scopus, and Cochrane Library were searched until December 19, 2022, without any restrictions. The quality assessment of each study was performed based on the Newcastle-Ottawa Scale tool. The Review Manager 5.3 software presented the effect sizes including odds ratio (OR) along with a 95% confidence interval (CI). Both publication bias and sensitivity analyses were carried out by the Comprehensive Meta-Analysis version 2.0 software. A total of 2,508 records were identified among databases and at last, 27 articles were entered into the meta-analysis. Seven polymorphisms of IL-6 were entered into the analyses. Just rs1800797 polymorphism in the dominant model (OR = 1.51; 95% CI = 1.15–2.00; P = 0.003) and rs2069840 polymorphism in heterozygous (OR = 0.89; 95% CI = 0.81–0.97; P = 0.008) and dominant (OR = 0.91; 95% CI = 0.84–0.99; P = 0.02) models had a significant association with the BC risk. In conclusion, among 7 polymorphisms and despite a few included cases, the present meta-analysis recommended that the AA+GA genotype of rs1800797 polymorphism had a significantly elevated risk and the GC and the CC+GC genotypes of rs2069840 polymorphism had a protective role in the BC patients.
Get full access to this article
View all access options for this article.
References
1.
AbanaCO, BinghamBS, ChoJH, et al.IL-6 variant is associated with metastasis in breast cancer patients. PLoS One, 2017; 12(7):e0181725; doi: 10.1371/journal.pone.0181725
2.
AleaghaO, OltuluP, SadeghiM. Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: A meta-analysis. Clin Exp Hepatol, 2020; 6(4):359–366; doi: 10.5114/ceh.2020.102171
3.
AlshatwiAA, HasanTN, ShafiG, et al.Genetic variation in IL-6 and TNF-α genes with risk of breast cancer in a Saudi population-based case-control study. Breast J, 2012; 18(4):383–385; doi: 10.1111/j.1524-4741.2012.01260.x
4.
AlSuhaibaniES, KizilbashNA, MalikS, et al.Polymorphisms in promoter regions of IL-6 and IL-10 genes in breast cancer: A case-control study. Genet Mol Res, 2016; 15(1); doi: 10.4238/gmr.15017360
5.
AmirifardN, PayandehM, AeinfarM, et al.A survey on the relationship between emotional intelligence and level of depression and anxiety among women with breast cancer. Int J Hematol Oncol Stem Cell Res, 2017; 11(1):54–57.
6.
AmirifardN, SadeghiE, PayandehM, et al.Relationship between HER2 proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev, 2016; 17(1):295–298.
7.
BalasubramanianSP, AzmyIA, HighamSE, et al.Interleukin gene polymorphisms and breast cancer: A case control study and systematic literature review. BMC Cancer, 2006; 6:188; doi: 10.1186/1471-2407-6-188
8.
BarekMA, BegumM, NoorF, et al.The link between IL-6 rs2069840 SNP and cancer risk: Evidence from a systematic review and meta-analysis. Meta Gene, 2021; 30:100972.
9.
BeggCB, MazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994; 50(4):1088–1101.
10.
BellR, BarracloughR, VasievaO. Gene expression meta-analysis of potential metastatic breast cancer markers. Curr Mol Med, 2017; 17(3):200–210; doi: 10.2174/1566524017666170807144946
11.
BenzCC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol, 2008; 66(1):65–74; doi: 10.1016/j.critrevonc.2007.09.001
12.
Beyranvand NejadE, LabrieC, van der SluisTC, et al.Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function. Int J Cancer, 2021; 148(1):211–225; doi: 10.1002/ijc.33280
13.
Cancer CGoHFiB. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 2001; 358(9291):1389–1399; doi: 10.1016/S0140-6736(01)06524-2
14.
CareyLA, PerouCM, LivasyCA, et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006; 295(21):2492–2502; doi: 10.1001/jama.295.21.2492
15.
ChangQ, BournazouE, SansoneP, et al.The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia, 2013; 15(7):848–862; doi: 10.1593/neo.13706
16.
ChenX-W, ZhouS-F. Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther, 2015; 9:2941; doi: 10.2147/DDDT.S86396
17.
ChérelM, CampionL, BézieauS, et al.Molecular screening of interleukin-6 gene promoter and influence of −174G/C polymorphism on breast cancer. Cytokine, 2009; 47(3):214–223; doi: 10.1016/j.cyto.2009.06.011
18.
ChoiKS, SongH, KimEH, et al.Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: Potential mechanisms of gastric cancer prevention by Korean red ginseng. J Ginseng Res, 2012; 36(2):135–145; doi: 10.5142/jgr.2012.36.2.135
19.
ChonovDC, IgnatovaMM, AnanievJR, et al.IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci, 2019; 7(14):2391–2398; doi: 10.3889/oamjms.2019.589
20.
CouchFJ, CerhanJR, VierkantRA, et al.Cigarette smoking increases risk for breast cancer in high-risk breast cancer families. Cancer Epidemiol Biomarkers Prev, 2001; 10(4):327–332.
21.
CoussensLM, WerbZ. Inflammation and cancer. Nature, 2002; 420(6917):860–867; doi: 10.1038/nature01322
22.
DeMicheleA, MartinAM, MickR, et al.Interleukin-6 − 174GC polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res, 2003; 63(22):8051–8056.
23.
DemirciU, YamanM, BuyukberberS, et al.Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol, 2012; 14(4):546–549; doi: 10.1016/j.intimp.2012.08.007
24.
DengT, LyonCJ, BerginS, et al.Obesity, inflammation, and cancer. Annu Rev Pathol Mech Dis, 2016; 11:421–449; doi: 10.1146/annurev-pathol-012615-044359
DossusL, KaaksR, CanzianF, et al.PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis, 2010; 31(3):455–461; doi: 10.1093/carcin/bgp307
27.
DuY, GaoL, ZhangK, et al.Association of the IL6 polymorphism rs1800796 with cancer risk: A meta-analysis. Genet Mol Res, 2015; 14(4):13236–13246; doi: 10.4238/2015.October.26.20
28.
EggerM, SmithGD, SchneiderM, et al.Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315(7109):629–634; doi: 10.1136/bmj.315.7109.629
29.
FerlayJ, ErvikM, LamF, et al.Global cancer observatory: Cancer today. IARC, 2018; 3(20):2019.
30.
GonulluG, BasturkB. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J, 2007; 28(11):1728–1733.
31.
Gonzalez-Zuloeta LaddAM, Arias VásquezA, WittemanJ, et al.Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol, 2006; 21(5):373–376; doi: 10.1007/s10654-006-9005-1
32.
GordeevaLA, MunSA, VoroninaEN, et al.Association between cytokine gene polymorphisms and breast cancer in postmenopausal women. Adv Gerontol, 2021; 11:44–52.
33.
GrivennikovS, KarinM. Autocrine IL-6 signaling: A key event in tumorigenesis?. Cancer Cell, 2008; 13(1):7–9; doi: 10.1016/j.ccr.2007.12.020
34.
HeKL, LiYP, LvYG, et al.[Association between polymorphisms of interleukin-6 gene promoter and breast cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2011; 27(11):1220–1222.
35.
HeflerLA, GrimmC, LantzschT, et al.Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res, 2005; 11(16):5718–5721; doi: 10.1158/1078-0432.CCR-05-0001
36.
HeinrichPC, BehrmannI, Müller-NewenG, et al.Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J, 1998; 334(2):297–314; doi: 10.1042/bj3340297
37.
HerbeuvalJP, LelievreE, LambertC, et al.Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol, 2004; 172(7):4630–4636; doi: 10.4049/jimmunol.172.7.4630
38.
HiranoT. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol, 1998; 16(3–4):249–284.
39.
HopperJL, DiteGS, MacInnisRJ, et al.Age-specific breast cancer risk by body mass index and familial risk: Prospective family study cohort (ProF-SC). Breast Cancer Res, 2018; 20(1):1–11; doi: 10.1186/s13058-018-1056-1
40.
HortobagyiGN. Trastuzumab in the treatment of breast cancer. N Engl J Med, 2005; 353:1734–1736.
IacopettaB, GrieuF, JosephD. The −174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer, 2004; 90(2):419–422; doi: 10.1038/sj.bjc.6601545
43.
ImbergerG, ThorlundK, GluudC, et al.False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: An empirical review. BMJ Open, 2016; 6(8):e011890; doi: 10.1136/bmjopen-2016-011890
44.
JabłonowskaE, KołacinskaA, KuydowiczJ, et al.Interleukin-6 and the IL-6 (−174) C/G polymorphism in breast pathologies and in HIV-infected patients. Arch Med Sci, 2010; 6(6):860–865; doi: 10.5114/aoms.2010.19292
45.
JavaleraD, Quintero-RamosA, Medina-MoraY, et al.The −174G>C and −596G>A polymorphisms are not associated with circulating IL-6 levels in breast cancer patients from Jalisco, México. Genet Test Mol Biomarkers, 2020; 24(4):224–228; doi: 10.1089/gtmb.2019.0141
46.
JonesME, SchoemakerMJ, WrightLB, et al.Smoking and risk of breast cancer in the Generations Study cohort. Breast Cancer Res, 2017; 19(1):1–14; doi: 10.1186/s13058-017-0908-4
47.
JoshiN, KannanS, KotianN, et al.Interleukin 6 − 174G>C polymorphism and cancer risk: Meta-analysis reveals a site dependent differential influence in Ancestral North Indians. Hum Immunol, 2014; 75(8):901–908; doi: 10.1016/j.humimm.2014.06.018
48.
KnüpferH, PreissR. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat, 2007; 102(2):129–135; doi: 10.1007/s10549-006-9328-3
49.
KumariN, DwarakanathBS, DasA, et al.Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol, 2016; 37(9):11553–11572; doi: 10.1007/s13277-016-5098-7
50.
LiangS, ChenZ, JiangG, et al.Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Cancer Lett, 2017; 386:12–23; doi: 10.1016/j.canlet.2016.11.003
51.
LitovkinKV, DomenyukVP, BubnovVV, et al.Interleukin-6 − 174G/C polymorphism in breast cancer and uterine leiomyoma patients: A population-based case control study. Exp Oncol, 2007; 29(4):295–298.
52.
LiuRY, SongX, ChenP, et al.Association between IL6 − 174G/C and cancer: A meta-analysis of 105,482 individuals. Exp Ther Med, 2012; 3(4):655–664; doi: 10.3892/etm.2012.454
53.
MadeleineMM, JohnsonLG, MalkkiM, et al.Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat, 2011; 129(3):887–899; doi: 10.1007/s10549-011-1520-4
54.
MaedaS, OmataM. Inflammation and cancer: Role of nuclear factor-kappaB activation. Cancer Sci, 2008; 99(5):836–842; doi: 10.1111/j.1349-7006.2008.00763.x
55.
MantelN, HaenszelW. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959; 22(4):719–748.
56.
McGuireA, BrownJA, MaloneC, et al.Effects of age on the detection and management of breast cancer. Cancers (Basel), 2015; 7(2):908–929; doi: 10.3390/cancers7020815
57.
MoherD, LiberatiA, TetzlaffJ, et al.Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Med, 2009; 6(7):e1000097; doi: 10.1371/journal.pmed.1000097
58.
NajafiS, SadeghiM, AbasvandiF, et al.Prognostic factors influencing prognosis in early breast cancer patients. Prz Menopauzalny, 2019; 18(2):82–88; doi: 10.5114/pm.2019.86833
59.
NajafiS, SadeghiM, ShajariMR, et al.The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemp Oncol (Pozn), 2018; 22(2):108–112; doi: 10.5114/wo.2018.77048
60.
NajafiS, SadeghiM, ShajariMR, et al.The impact of hormone receptor status on survival and recurrence of HER2-positive breast cancers in standard adjuvant setting: A retrospective study in Tehran, Iran. J Pak Med Assoc, 2020; 70(1):11–16; doi: 10.5455/JPMA.290165
61.
NicoliniA, CarpiA, RossiG. Cytokines in breast cancer. Cytokine Growth Factor Rev, 2006; 17(5):325–337.
62.
PadalaC, PuranamK, ShyamalaN, et al.Genotypic and haplotype analysis of interleukin-6 and -18 gene polymorphisms in association with clinicopathological factors in breast cancer. Cytokine, 2022; 160:156024; doi: 10.1016/j.cyto.2022.156024
63.
PayandehM, SadeghiM, SadeghiE, et al.Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 2015; 16(12):4863–4867.
64.
PayandehM, SadeghiM, SadeghiE, et al.Expression of p53 breast cancer in Kurdish women in the west of Iran: A reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev, 2016; 17(3):1261–1264.
65.
PengX, ShiJ, SunW, et al.Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: A meta-analysis. Oncotarget, 2018; 9(15):12351; doi: 10.18632/oncotarget.24033
66.
PoojaS, ChaudharyP, NayakLV, et al.Polymorphic variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine, 2012; 60(1):122–128; doi: 10.1016/j.cyto.2012.06.241
67.
RojasA, LiuG, ColemanI, et al.IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 2011; 30(20):2345–2355; doi: 10.1038/onc.2010.605
68.
Sa-NguanraksaD, SuntiparpluachaM, KulpromA, et al.Association of estrogen receptor alpha and interleukin 6 polymorphisms with lymphovascular invasion, extranodal extension, and lower disease-free survival in Thai breast cancer patients. Asian Pac J Cancer Prev, 2016; 17(6):2935–2940.
69.
SchonfeldSJ, BhattiP, BrownEE, et al.Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists. Cancer Causes Control, 2010; 21(11):1857–1866; doi: 10.1007/s10552-010-9613-7
70.
Shahriari-AhmadiA, ArabiM, PayandehM, et al.The recurrence frequency of breast cancer and its prognostic factors in Iranian patients. Int J Appl Basic Med Res, 2017; 7(1):40–43; doi: 10.4103/2229-516X.198521
71.
SharmaR. Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: Evidence from Global Burden of Disease Study 2016. Breast Cancer, 2019; 26:428–445; doi: 10.1007/s12282-018-00941-4
72.
ShiovitzS, KordeLA. Genetics of breast cancer: A topic in evolution. Ann Oncol, 2015; 26(7):1291–1299; doi: 10.1093/annonc/mdv022
73.
SiegelR, MaJ, ZouZ, et al.Cancer statistics, 2014. CA Cancer J Clin, 2014; 64(1):9–29; doi: 10.3322/caac.21208
74.
SkerrettDL, MooreEM, BernsteinDS, et al.Cytokine genotype polymorphisms in breast carcinoma: Associations of TGF-beta1 with relapse. Cancer Invest, 2005; 23(3):208–214; doi: 10.1081/cnv-200055954
75.
SlatteryML, CurtinK, SweeneyC, et al.Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring), 2008; 16(2):339–347; doi: 10.1038/oby.2007.44
76.
SlatteryML, HerrickJS, Torres-MejiaG, et al.Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: The Breast Cancer Health Disparities Study. Carcinogenesis, 2014; 35(8):1750–1759; doi: 10.1093/carcin/bgu078
77.
SmithKC, BatemanAC, FussellHM, et al.Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet, 2004; 31(4):167–173; doi: 10.1111/j.1365-2370.2004.00462.x
78.
SnoussiK, StrosbergAD, BouaouinaN, et al.Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw, 2005; 16(4):253–260.
79.
StangA. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010; 25:603–605; doi: 10.1007/s10654-010-9491-z
80.
SullivanNJ, SasserAK, AxelA, et al.Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene, 2009; 28(33):2940–2947; doi: 10.1038/onc.2009.180
81.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/caac.21660
82.
SzklarczykD, FranceschiniA, WyderS, et al.STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 2015; 43(D1):D447–D452; doi: 10.1093/nar/gku1003
83.
TerryCF, LoukaciV, GreenFR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 2000; 275(24):18138–18144; doi: 10.1074/jbc.M000379200
84.
UciechowskiP, DempkeWC. Interleukin-6: A masterplayer in the cytokine network. Oncology, 2020; 98(3):131–137; doi: 10.1159/000505099
85.
VogelU, ChristensenJ, NexøBA, et al.Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis, 2007; 28(2):427–434; doi: 10.1093/carcin/bgl170
86.
WangL, YiT, KortylewskiM, et al.IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med, 2009; 206(7):1457–1464; doi: 10.1084/jem.20090207
87.
WetterslevJ, JakobsenJC, GluudC. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol, 2017; 17(1):1–18; doi: 10.1186/s12874-017-0315-7
88.
WirapatiP, SotiriouC, KunkelS, et al.Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res, 2008; 10(4):1–11; doi: 10.1186/bcr2124
89.
XuB, NiuXB, WangZD, et al.IL-6 − 174G>C polymorphism and cancer risk: A meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep, 2011; 38:2589–2596; doi: 10.1007/s11033-010-0399-1
90.
XuG, WangF. Associations of polymorphisms in interleukins with susceptibility to breast cancer: Evidence from a meta-analysis. Cytokine, 2020; 130:154988; doi: 10.1016/j.cyto.2020.154988
91.
YuKD, DiGH, FanL, et al.Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: A meta-analysis involving 25,703 subjects. Breast Cancer Res Treat, 2010; 122:483–488; doi: 10.1007/s10549-009-0706-5
92.
ZhaiK, YangY, GaoZG, et al.Interleukin-6-174G> C gene promoter polymorphism and prognosis in patients with cancer. Oncotarget, 2017; 8(27):44490; doi: 10.18632/oncotarget.17771
93.
ZhangZ, ChenZ, ChenD, et al.Association between IL-6-572 C/G polymorphism and breast cancer susceptibility. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2016; 32(12):1667–1670.
94.
ZhouL, ZhengY, TianT, et al.Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls. Gene, 2018; 670:136–147; doi: 10.1016/j.gene.2018.05.104
95.
ZhuRM, LinW, ZhangW, et al.Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival. PLoS One, 2017; 12(6):e0178850; doi: 10.1371/journal.pone.0178850
